Liquid Dosage
Insulin
With diabetes on the rise and the global insulin market estimated to be worth more than $32 billion by 2018, demand for GEA technologies for the production of this life-saving drug is already high and set to increase, particularly in new markets and emerging economies.
State-of-the-Art Solutions
GEA produces and supplies process systems for the production of liquid products for the pharmaceutical and biotechnological industries, and has a proven history of successfully installing plant for the production of insulin, including the engineering, delivery, commissioning and qualification of entire ultra-pure media systems as well as various process equipment and cleaning installations.
A worldwide technology leader in insulin production, GEA is able to supply the clean utility systems and manage the integration of all the main processes, including fermentation, harvesting, chromatography, filtration and freeze drying.
From Fermentation to Freeze Drying
The biosynthetic production of human insulin is done using bacteria or yeast cells. Following fermentation, or the conversion of chemical raw materials by micro-organisms, the biomass is extracted using a nozzle separator, washed, concentrated and finally precipitated to produce insulin crystals.
Centrifuges and process lines provided by GEA have an established pedigree in the clarification, separation, classification, concentration and fractionation steps. Nozzle separators also play an important part in the production process. Further, GEA chamber or self-cleaning separators can be used in the subsequent crystallization stages.
GEA is a single-source supplier of a variety of fermenters, media preparation, buffer storage, harvesting and cell rupture solutions, equipment for the purification and isolation of cells, separation (after both first and final crystallization), the production and distribution of WFI, CIP and freeze drying technologies, all of which can be installed and integrated into a state-of-the-art insulin production facility.
Produkte und Technologien
Zeigt 4 von 14 an
Aseptic valves & components
Aseptic valves face exceptionally high demands within UltraClean and Aseptic processes. You can be assured that they all provide highest quality in terms of hygienic design and sustainability.
CIP/SIP-Lösungen
Innovative CIP-Konzepte von GEA erfüllen umfassende hohe Normen. Unsere Experten garantieren die Produktsicherheit an jeder Stelle des Prozesses. Jede Aktualisierung wird an die individuellen lokalen Bedingungen und Anforderungen der Kunden angepasst und führt zu erheblichen Einsparungen.
GEA Hygienische Pumpen
GEA Hilge offers a versatile range of centrifugal and positive displacement pumps for a wide variety of sensitive applications in the beverage, food and pharmaceutical industries.
Homogenisierungs-Kompressionsblock
Die GEA Kompressionsblöcke sind der pulsierende Kern der Homogenisierungsanlagen, da sie die Homogenisierung aktivieren, indem sie das Produkt mit hohem Druck pumpen, bis es innerhalb des Homogenisierventils zu fließen beginnt.
Downloads
GEA Insights
Kytero 10 - grosse Veränderungen beginnen im Kleinen
Mit dem GEA kytero 10 steht Forschenden und Entwicklern in der Biopharma-, Lebensmittel- und New Food-Industrie nun die neueste Generation eines leistungsstarken Beschleunigers zur Seite.
Wärmepumpentechnologie reduziert den Kohlenstoffausstoß der Industrie
Von Kosteneinsparungen bis zur Emissionsreduzierung: GEA ist führend bei innovativen Wärmepumpentechnologie-Projekten. Informieren Sie sich über traditionelle und Fernwärme-Initiativen.
Auf dem Speiseplan: nachhaltigere Eier
GEA unterstützt Kunden beim Testen und Skalieren alternativer Eiprodukte und Zutaten, die durch Präzisionsfermentation hergestellt werden.
